UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000016959
Receipt number R000019602
Scientific Title Effect of Lixisenatide on Gastric Emptying in Japanese T2DM Patients Analysed by C13 Breath Test
Date of disclosure of the study information 2015/04/01
Last modified on 2016/04/29 10:27:29

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Effect of Lixisenatide on Gastric Emptying in Japanese T2DM Patients Analysed by C13 Breath Test

Acronym

Effect of Lixisenatide on Gastric Emptying in Japanese T2DM Patients

Scientific Title

Effect of Lixisenatide on Gastric Emptying in Japanese T2DM Patients Analysed by C13 Breath Test

Scientific Title:Acronym

Effect of Lixisenatide on Gastric Emptying in Japanese T2DM Patients

Region

Japan


Condition

Condition

T2DM

Classification by specialty

Endocrinology and Metabolism

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To explore the effect of lixisenatide on gastric emptying, a major determinant of postprandial glycemia, using C13-acetate breath test

Basic objectives2

Pharmacodynamics

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Tlag (Tmax-cal) and T1/2 on C13-acetate breath test carried out after insulin/lixisenatide treatment

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Self control

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Antidiabetic treatment carried out before admission is switched to insulin therapy on admission. The dose of insulin is titrated up to achieve a target fasting plasma glucose level of less than 140 mg/dl. Lixisenatide therapy is subsequently initiated at 10 microgram QD, and the dose is increased in increments of 5 microgram at 1- or 2-day intervals to a maximum level of 20 microgram QD.

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

80 years-old >=

Gender

Male and Female

Key inclusion criteria

(1)Japanese T2DM patients
(2)Patients treated with OAD and/or injection therapy including insulin and GLP-1 receptor agonist except lixisenatide
(3)HbA1c >= 7.0% at screening visit
(4)Male and female patients aged 20-80 years

Key exclusion criteria

(1)Patients with history of chronic pancreatitis, inflammatory bowel disease, pancreatectomy or gastrectomy
(2)Patients with history of metabolic acidosis including diabetic ketoacidosis during the previous 1 year
(3)Patients with history of stroke or myocardial infarction requiring hospitalization during the previous 6 months
(4)Patients with severe or uncontrolled congestive heart failure
(5)Patients with drug or alcohol abuse during the previous 6 months
(6)Patients having hepatic dysfunction with AST or ALT greater than 5 times the upper limit of the normal laboratory range at the time of screening
(7)Patients having uncontrolled hypertension with a resting systolic blood pressure greater than 180 mm Hg or diastolic blood pressure greater than 110 mmHg at the time of screening
(8)Patients with end-stage renal dysfunction and/or dialysis
(9)Patients having clinically relevant history of gastrointestinal disease with prolonged nausea and vomiting during the previous 6 months
(10)Pregnant or possibly pregnant women
(11)Patients judged as inadequate to participate in the present study by investingator or sub-investigator

Target sample size

20


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Makoto Ohashi

Organization

Osaka Rosai Hospital

Division name

Center for Diabetes Mellitus

Zip code


Address

1179-3 Nagasone-cho, Sakai, Osaka 591-8025, Japan

TEL

072-252-3561

Email

otokam@osakah.johas.go.jp


Public contact

Name of contact person

1st name
Middle name
Last name Yoshimoto Kiyohara

Organization

Osaka Rosai Hospital

Division name

Center for Diabetes Mellitus

Zip code


Address

1179-3 Nagasone-cho, Sakai, Osaka 591-8025, Japan

TEL

072-252-3561

Homepage URL


Email

y-kiyohara@osakah.johas.go.jp


Sponsor or person

Institute

Osaka Rosai Hospital

Institute

Department

Personal name



Funding Source

Organization

Japan Labour Health and Welfare Organization

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

大阪労災病院 / Osaka Rosai Hospital


Other administrative information

Date of disclosure of the study information

2015 Year 04 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Enrolling by invitation

Date of protocol fixation

2015 Year 02 Month 26 Day

Date of IRB


Anticipated trial start date

2015 Year 04 Month 01 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2015 Year 03 Month 29 Day

Last modified on

2016 Year 04 Month 29 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000019602